Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

Lancet

Volumn 352, Issue 9131, 1998, Pages 837-853

  Turner, Robert ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A; HUMAN INSULIN; INSULIN; INSULIN ZINC SUSPENSION; SULFONYLUREA;

ADULT; AMPUTATION; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY FAILURE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; STROKE; SUDDEN DEATH; VASCULAR DISEASE;

EID: 0032511583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07019-6     Document Type: Article

References (47)

1. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230: 101-08.
2. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
4. UKPDS Group. UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-45.
5. Fuller J, McCartney P, Jarrett RJ. Hyperglycaemia and coronary heart disease: the Whitehall Study. J Chronic Dis 1979; 32: 721-28.
6. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 1998; 21: 360-67.
7. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes VII: mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240: 37-42.
8. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1976; 25: 1129-53.
9. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetologia 1995; 38: 116-21.
10. Pogatsa G. Potassium channels in the cardiovascular system. Diabetes Res Clin Pract 1995; 28 (suppl 1): S91-S98.
11. Stout RW. Insulin and atherosclerosis. In: Stout RW, ed. Diabetes and atherosclerosis. Dordrecht: Kluwer Academic Publishers, 1992: 165-201.
12. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 104-09.
13. UKPDS Group. UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 1991; 34: 877-90.
14. Metropolitan Life Insurance Company. Net weight standard for men and women. Stat Bull Metrop Insur Co 1959; 40: 1-4.
15. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
16. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996; 39: 1554-61.
17. Holman RR, Cull CA, Turner RC. Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients. Diabetologia 1996; 39 (suppl 1): A44.
18. UKPDS Group. UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994; 11: 534-44.
19. Manley SE, Burton ME, Fisher KE, Cull CA, Turner RC. Decreases in albumin/creatinine and N-acetylglucosaminidase/creatinine ratios in urine samples stored at -20°C. Clin Chem 1992; 38: 2294-99.
20. World Health Organisation. International Classification of Procedures in Medicine. Geneva: World Health Organisation, 1978.
21. UKPDS Group. UK Prospective Diabetes Study IX: relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of type 2 (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy. Diabetologia 1992; 36: 835-42.
22. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998; 21 (suppl 1): S5-19.
23. World Health Organization. Diabetes mellitus. WHO technical report series no 727. Geneva: WHO, 1985.
24. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care 1990; 13: 631-54.
25. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-41.
26. Desprès JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-57.
27. Davies EG, Petty RG, Kohner EM. Long term effectiveness of photocoagulation for diabetic maculopathy. Eye 1989; 3: 764-67.
28. British Multicentre Group. Photocoagulation for proliferative diabetic retinopathy: a randomised controlled clinical trial using the xenon-arc. Diabetologia 1984; 26: 109-15.
29. Schmitt JK, Moore JR. Hypertension secondary to chlorpropamide with amelioration by changing to insulin. Am J Hypertens 1993; 6: 317-19.
30. Melander A. Sulphonylureas in the treatment of non-insulin-dependent diabetes. Baillieres Clin Endocrinol Metab 1988; 2: 443-53.
31. DCCT Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 1415-27.
32. UKPDS Group. UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes 1995; 44: 1249-58.
33. UKPDS Group. UK Prospective Diabetes Study 26: sulphonylurea failure in non-insulin dependent diabetic patients over 6 years. Diabet Med 1998; 15: 297-303.
34. UKPDS Group. UK Prospective Diabetes Study 28: a randomised trial of efficacy of early addition of metformin in sulphonylurea-treated non-insulin dependent diabetes. Diabetes Care 1998; 21: 87-92.
35. Kumar S, Boulton AJ, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-09.
36. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1996; 121: 928-35.
37. Birkeland KI, Rishaug U, Hanssen KE, Vaaler S. NIDDM: a rapid progressive disease. Diabetologia 1996; 39: 1629-33.
38. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-33.
39. Chow CC, Tsang LWW, Sorensen JP. Comparison of insulin with or without continuation of oral hypoglycaemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-14.
40. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998; 21 (suppl 1): S23-S31.
41. Abraira C, Colwell JA, Nuttall FQ. Veterans Affairs Cooperative Study on glycemic control and complications in Type II diabetes (VACSDM). Diabetes Care 1995; 18: 1113-23.
42. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6 month outpatient trial. Diabetes Care 1993; 16: 21-31.
43. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with Type 2 diabetes. JAMA 1997; 278: 1663-700.
44. Dunn NR, Bough P. Standards of care of diabetic patients in a typical English community. Br J Gen Pract 1996; 46: 401-05.
45. American Diabetes Association. Clinical practice recommendations 1998. Diabetes Care 1998; 21 (suppl 1): S20-S22.
46. de Courten M, Zimmet P. Screening for non-insulin-dependent diabetes mellitus: where to draw the line? Diabet Med 1997; 14: 5-98.
47. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317: 703-13.